<SEC-DOCUMENT>0001075880-12-000002.txt : 20120103
<SEC-HEADER>0001075880-12-000002.hdr.sgml : 20120102
<ACCEPTANCE-DATETIME>20120103165343
ACCESSION NUMBER:		0001075880-12-000002
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120104
FILED AS OF DATE:		20120103
DATE AS OF CHANGE:		20120103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		12502701

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20120103.htm
<DESCRIPTION>FORM 6K 2011 01 03
<TEXT>
<html>
<head>
    <title>form6k20120103.htm</title>
    <!--Licensed to: Novogen Laboratories-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5%; FONT-SIZE: 14pt; MARGIN-RIGHT: 5%">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">For the month of January, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Commission File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">140 Wicks Road, North Ryde, NSW, Australia</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive office)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Form 20-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf </font>by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">/s/&#160;&#160;Ron Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Ronald Lea Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Company Secretary</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Date 3 January, 2012</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right">
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="3"><img src="novogenlogo.jpg" alt=""></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">ASX &amp; MEDIA RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">3 JANUARY 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">MARSHALL EDWARDS ISSUED NEW METHOD OF USE PATENT FOR LEAD ONCOLOGY DRUG CANDIDATE ME-344</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Novogen Limited&#8217;s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">San Diego &#8211; 3 January, 2012 &#8211; Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the US Patent and Trademark Office has issued a new method of use patent, US Patent No. 8,084,628, covering a number of the company&#8217;s mitochondrial inhibitor compounds, including lead drug candidate ME-344, for the treatment of cancer or a tumour mass.&#160;&#160;The patent is expected to provide protection until September, 2025.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Treatment of tumour cells with the company&#8217;s mitochondrial inhibitor compounds induces a rapid loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways.&#160;&#160;T he company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application forME-344 this quarter, and expects to initiate a Phase I clinical trial of intravenous ME-344 shortly thereafter.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">&#8220;Given the increased interest in oncology compounds that can impact both the mTOR1 and mTOR2 pathways, we are particularly pleased to receive patent coverage for the use of ME-344 in cancer,&#8221; said Daniel P Gold, PhD, President and Chief Executive Officer of Marshall Edwards.&#160;&#160;&#8220;This new patent reaffirms our ongoing commitment to expanding and strengthening our intellectual property portfolio while adding to the value of our drug development pipeline.&#160;&#160;A strong patent estate is essential to the commercial potential of our drug candidates and should be recognised by potential partners.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">About Marshall Edwards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Marshall Edwards, Inc., is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics.&#160;&#160;The company&#8217;s lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism.&#160;&#160;The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143.&#160;&#160;The company initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and expects final data from the trial by the second quarter of 2012.&#160;&#160;The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344.&#160;&#160;The company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012.&#160;&#160;For more information, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.marshalledwardsinc.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">About Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Novogen Limited (ASX: NRT&#160;&#160;Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia.&#160;&#160;Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc.&#160;&#160;More information on the Novogen group of companies can be found at www.novogen.com.</font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenlogo.jpg
<TEXT>
begin 644 novogenlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!"`,\#`2(``A$!`Q$!_\0`
M'``!`0$!`0`#`0````````````<&!0@!`P0"_\0`1A```0,#`@,&`@4'"`L`
M`````0`"`P0%$08A!Q)!$R(Q46&!%'$(%3*1H187(S1T@K$S.%)RL\'1X4)&
M5%9B=9*3HL+2_\0`&@$!``,!`0$```````````````(#!`$%!O_$`#(1``$#
M`@4"!`4"!P````````$``A$#!!(3(3%!47$%%(&A(C)2D<%AL2,S0D/1X?'_
MV@`,`P$``A$#$0`_`/5*(B(B(B(B(B(B^BKJ8Z5L3I7!H?(V,$]2XX`^_"^]
M8OC#/4TG#ZXU=$XMJ*9\,['#H6RL.?P70),*%1^!A=T"VB+/Z$U12:NT[3W.
MD+0]PY9X0<F*0>+3_$>8(6@0B-"NM<'@.;L41$7%)$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$12'B%Q%O.FM;/H:6*GEM\,<4TC'1DN+3]KO`[;*#WA@DK1;6S[
ME^73W5>1?DM-PI[K;*6OHG\]-41B1A]".OJL;Q8U5<M+TUIDM?89J:GLY.U9
MS=W;PW]5US@T8BH4J+ZM3+;NMZB*8ZLXBUIOCK!HJ@;<KFUQ9)*X]QCAX@#;
M..I)`'JCGANZ[0MWUS#!MOT`_54Y9SB/1FOT%?Z=K>9SJ.1S1ZM;S#\0L74#
MBQ14YJ^VM-86CF=2L8.;'C@;#/EL5VM`:^IM7"HM=RI307B-KFS4S_!X&SN7
M.^W5IW'JN-JC$`=%.M8ORW.:0X<P9A><>'FLJW1E\;64N9*63#*FG)P)69_!
MPZ'_`!*]=V"\45^M%-<K9*):6H;S-/4>;2.A!V(\UXOU/:I+'J&XVR7/-2SN
MC!/4`['W&"J)]'_6#[-J,66KEQ;KB[#`X[1S?Z)'];[)_=\EOK,#AB"^3\-N
MG4:F0_8^Q7IQ$6%L>J+A>>)5WM5*8#9;;&&R.#,N=+L,<W3?FV_X5B+@%]/3
MI.J!Q'`DK=(IQKOB.^UW9MATS0_6E\<>4M`)9&<9Q@;DXW/0=3T7X#'Q9%*:
MKXBTN>!GX4-;S'TSC&?=0-43`U6AMD\M#GD-G:3$JK(I[H'B$^\W*2R:AH?J
MR^1DM[,YY92!D@`^!QOC)SYJA.(:"7$`#<D]%)K@X2%16H/H.PO"(I5=.(MW
MOEVGM?#VV-KG0Y;+6S?R;3G`(W`QL=R=_)?$C.+-,P3MEM%6?$T[6M&/3)`^
M7BH9HX$K1Y%X'QN#3T)U5619_0UQO5SLG;ZDMK;=7-E='V;2>\T>#L;XSOU/
MGU66XA:GU'0:QM5CTTVD=+64YD`G;XN#CUSL,!2+P!B*J9;/?4-,$2)YTT_5
M4E%+^UXK?[/9?^L+>Z:=='62E.H&0,NG*>W;`<LSD^'MA=:Z>%RK0RQ.('L5
MTT46TQQ5N#]7?!7YM.+;+4/I62QQEIC?S$,R<XQMO\\JTKC'A^H7;BUJ6Q`J
M<B418&35=Q;Q?BTV.Q^K7TW:GN=_FY"?'/F%OE(.!V5=2DZG&+D2BC-YH:>Y
M<?Q15L39::>W.CD8[P(,3E9E(I_YQU/^PG^S<JZO'=:;$D%Y'TE?/#6NGTAJ
MNNT5>)3V+W&:W2/.S@23@'U&^/,.7]?2#_4=/_MG_P`KL\8M+R7BRQW:V!S;
MQ:LSPN9]IS1@D#&^1C(]1ZK`\0=3,U9HO3%P#>2H;6]E41_T)!RY]CXCYJI_
MPM+#Z+T;89]9ERW?4.[P=?7]U7^(%TDLNC+O7P9$L4!#"#@ASNZ#[9S[+,<"
M['#;]'Q7-S>:LN)=*Z1P[P9G`;GVSZDK0<3;?)<]!WFF@`,I@[1H]6D.V]=E
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MIIN7]1%0YH.`9.7=H_>V64X602V+AM=-0U>375@FKG.D))(:#RY^9!/NIS8[
MK-=^&%ATG2/'Q%9<WP.V^S&"'[^F7Y_=7H&]6ELND*VTT3.5AHGT\3&[8[F&
MC^"P5!_$,<+ZVU>!9TR_^X03V'^Y^RGW`&SAULKM15K"^X5LSF"5^[N48+CG
MU=G[E6E+^`%U94Z4GMLCP*JBG<3&1@ACMQ\]^8*H+E",`A6>)EWFGAW7VX]E
M(>/EL;1TUMU/1?HJZDG;&Y[-BX>+22/(MQ\B0NOQ6U%)!PPCJ:?FCFNC(HQR
MG!:'MYG;_P!4$>ZY_P!(2XQBP4%FC<365M2U[6MW(:WK[N+0%]O%RQS#A521
MM([6UB%[R/#`;R./_EGV5;Y!?AZ+9;PYMOG;8C';_JU7#6PPZ?T?;Z:)@;-+
M&V>=W5TC@"?NV'LM0L]P_O,%]TC;:N!P+A$V*5N<EDC0`X'W_`A:"0D,<1X@
M%7LC"(V7E7!>:KLS>3*^5)M>5E-;^,^EJJMF9!3QTC^>20X:W)>-S\RNQP7U
M#<]1V"OJ;Q4_$31U;HV'D:WE;R@XV`\UQ.(5NI+MQBTQ0W&!L])-2/#XW9P[
M!>>GJ`J7NQL#AU6^VHY%P^G4X:Z8[<+>MUGIIS@UM]MQ).`!.W_%=]8]G#31
M['M>VQTX<TAP/._8@Y!^TM@KFXOZEAK9.F3/K'X4`T9I>/5>F-9T8:/C&7!T
ME*_P+9!G`SY'P/\`DJ%PAU1)?+));[F[%YMKNPJ&.V<YHV#B#]Q]1ZKB\!?]
M:_\`F)_O7T\1:*HT9K"DUM:8'/II7"&XQ,SN#MS>^W[P!ZJAOP@/'JO3JG/J
M/MG;[M[QMZ_ND_\`..I_V$_V;E75&Z>KAK_I`V^KI7B2GGMPDC<.K3$2%9%9
M2Y[K%>@C+!^D?E%-9;%<W<<X;P*.3ZL;1\AJ-N7FY",?>52D4W-Q0L]*J:4Q
MR"/NB\^<1.']RH-4A^GJ"KJ;75S,J3'`WF;"_F[P(Z#J/0D=%Z#11J4Q4$%7
M6=X^T>7,UGA#N,'P4AO6CM0Z2U#-?-`\L]+.>:HMSSX[Y(`/B/'&.\,E5Y%U
M[`[=5T+AU`G#J#N#L5)GZ]UO5,%-1:(GAK=@Z2;F[,$]=P/XKH\/M!5M#>)=
M1ZKJ6U=\F&0T8+8B1@G/@3C88V`\%2$413UEQE7.O(:64FAH.\;_`'/"+F:E
ML=%J*S5-LN<0DIYFX]6.Z.!Z$+IHK=EA(#A!4%X,:#K[+Q!NLETIY1!;0603
M.9ADSG9`<WS[N3MX9"O2(AU)/5&RUC:?#1`[3/Y4JU;H6[VW4;]3:%F9'6/.
M9Z-Q`$F3EV,[8.,D'KN"OK_.!K7LC3_D+4_'X^WW^S\?+'_LJRBJRX/PF%O%
M[B:!68'1L3,^VZE>C-#7:OU`-3:\E;-<&D.IZ5I!;$1X$XV&.@'4Y.ZJ,\,=
M1!)#.QLD4C2Q['#(<#L05_:*;6!H@*BO</KNQ.XV'`[*-R:0U5H.YS5>B'MN
M%KE)<^AE.X'08SN1T(P?1?K;Q"UC-$Z%FA*OXD=TEW.&Y]V_WJLHH"EA^4PM
M!O14UK,#CUU!]8W4_P""^G;EIS3E5!>*<4\\]296Q\X<0WE`WQ\ER^)-!J"+
MB!9+Y8+0^XBCIG-(R`WF+G9!W'1RJB+N4,(:H>=>:SJY`DSVUT4L_*_B'_N0
MS_O?YK>Z6K;E<+)!47JA%!7.+N>G!SRX)QO\L+K(I!I'*IJ50\0&`=I_RIQP
M<LMRLYU&+G1RTPGKC)$7X[[=]QNMW>+;37BUU5OKH^TIJAAC>WT/4>H\5^Q$
M:T`0E2LZI4S-BH1P\TA>[#Q1IVUE'5OM](R:*.L<W]&6<IY,'IG/AYY5W1%R
MG3#!`5EW=NNGA[QJ!"(B*:RHB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
+B(B(B(B(B(B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
